Twist Bioscience Hits Record Revenue with 23% Year-Over-Year Growth: Unlocking the Power of Precision Genetics
Twist Bioscience, a leading provider of precision genetics and synthetic biology solutions, has achieved yet another milestone in its growth trajectory. The company recently reported record revenue of $118.4 million for its fiscal 2026 third quarter, representing a 23% year-over-year increase.
The impressive financial performance is a testament to Twist Bioscience's dedication to innovation and customer-centric approach. Under the leadership of CEO Emily Leproust, the company has been able to capitalize on emerging trends in biotechnology and synthetic biology, positioning itself at the forefront of precision genetics.
"This morning we reported our 14th quarter of consecutive growth with record revenue," Leproust stated during the company's conference call. "This growth reflects the diligence and execution we have employed over the last several years, building for opportunities we see ahead." Leproust emphasized that Twist Bioscience has been able to stay nimble and engage with its customers in real-time, ensuring that it delivers solutions tailored to their needs.
One of the key drivers behind Twist Bioscience's success is its unique ability to combine computational biology with precision genetics. The company's infrastructure enables its customers to advance therapeutics, diagnostics, and industrial breakthroughs, making it an indispensable partner in the life sciences industry.
The increasing adoption of artificial intelligence (AI) and machine learning (ML) approaches in biotechnology has further boosted Twist Bioscience's growth. Leproust noted that AI is shifting workflows across multiple industries, with large pharma, biotech companies, and even major technology firms leveraging AI as their first antibody discovery screen.
"Our customer can now design more sequences, test more hypotheses, and iterate faster than ever before," Leproust said, highlighting the transformative power of AI in drug discovery. The company's customers are using Twist Bioscience's solutions to design new models, conduct discovery for specific therapeutic targets, and refine their approaches.
The durability and longevity of AI-enabled discovery as a growth driver for Twist Bioscience is also evident from its customer base. Repeat business, new customer acquisition, and the expansion of existing organizations into the life sciences area have all contributed to the company's increasing confidence in this trend.
Twist Bioscience's record revenue and 23% year-over-year growth are a testament to its success in navigating the rapidly evolving biotechnology landscape. As precision genetics continues to shape the future of therapeutics, diagnostics, and industrial applications, Twist Bioscience is well-positioned to remain a leader in this field.
